Study guide
2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support
Key Takeaways Explain This Topic AI
Symptomatic bradycardia management requires rapid differentiation between hemodynamically stable patients (requiring monitoring and etiology evaluation) and unstable patients displaying hypotension, altered sensorium, shock, ischemic chest pain, or acute heart failure.
Atropine 1 mg IV push (repeated every 3 to 5 minutes to a maximum of 3 mg) is the first-line pharmacologic agent for symptomatic sinus bradycardia, but it is ineffective in infranodal blocks (Mobitz II second-degree or third-degree AV block with wide QRS) and denervated transplanted hearts.
Second-line chronotropic support when atropine fails or is contraindicated consists of continuous infusions of dopamine (5 to 20 mcg/kg/min), epinephrine (2 to 10 mcg/min), or isoproterenol (2 to 10 mcg/min), alongside immediate preparation for transcutaneous pacing.
Specific toxicologic and metabolic etiologies require targeted antidotal therapies: high-dose insulin euglycemia therapy (HIET) and calcium for beta-blocker/calcium channel blocker toxicity, and intravenous calcium chloride for membrane stabilization in hyperkalemia.
Last updated: October 2026
2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support
Bradycardia is defined electrophysiologically as a heart rate < 50 bpm <50\text{ bpm} < 50 bpm in adults. However, clinical management in the emergency setting is dictated by the presence or absence of end-organ hypoperfusion rather than an isolated numeric cutoff. When cardiac output declines secondary to inadequate chronotropy, the emergency medicine pharmacist must guide rapid pharmacologic escalation, recognize anatomical and pharmacodynamic limitations of first-line agents, prepare vasoactive infusions, and address toxicologic and ischemic drivers.
Identification of Hemodynamically Unstable Bradycardia
Patients presenting with bradycardia fall into two clinical categories:
Asymptomatic / Stable Bradycardia : The patient maintains adequate perfusion without signs of shock or ischemia. Management focuses on obtaining a 12-lead ECG, establishing continuous cardiac telemetry, and evaluating for reversible underlying causes (e.g., athletic conditioning, hypothyroidism, obstructive jaundice, or baseline nodal medications). Routine pharmacotherapy is not indicated.
Symptomatic / Unstable Bradycardia : The bradycardia is directly producing signs or symptoms of systemic hypoperfusion:
Hypotension : Systolic BP < 90 mmHg <90\text{ mmHg} < 90 mmHg or MAP < 65 mmHg <65\text{ mmHg} < 65 mmHg .
Acutely Altered Mental Status : Lethargy, confusion, syncope, or presyncope.
Signs of Shock : Diaphoresis, cyanosis, delayed capillary refill, cool extremities.
Ischemic Chest Discomfort : Angina or ischemic ECG changes driven by low coronary perfusion.
Acute Decompensated Heart Failure : Pulmonary edema or severe orthopnea.
Unstable patients require immediate resuscitation following the ACLS bradycardia algorithm.
First-Line Pharmacotherapy: Atropine Sulfate
Atropine is a competitive antagonist at postganglionic muscarinic acetylcholine receptors (predominantly M 2 M_2 M 2 receptors in cardiac tissue). By blocking vagal parasympathetic input to the sinoatrial (SA) and atrioventricular (AV) nodes, atropine abolishes vagal inhibitory tone, accelerates SA nodal automaticity, and shortens AV nodal conduction time.
Dosing and Administration Protocol
Dose : 1 mg IV push administered rapidly, repeated every 3 to 5 minutes as needed.
Maximum Cumulative Dose : 3 mg (which achieves complete vagal blockade in adult humans; doses beyond 3 mg provide no additional parasympathetic antagonism).
The 1 mg Starting Dose Rationale : Historical guidelines recommended 0.5 mg boluses. The ACLS update established 1 mg as the minimum initial dose because subtherapeutic doses ( < 0.5 mg <0.5\text{ mg} < 0.5 mg ) or slow IV administration block presynaptic inhibitory M 1 M_1 M 1 autoreceptors on parasympathetic nerve endings. This presynaptic blockade promotes paradoxical acetylcholine release before postsynaptic M 2 M_2 M 2 blockade occurs, triggering paradoxical bradycardia or transient high-grade AV block.
Anatomic and Pharmacologic Limitations: When Atropine Fails
Atropine is not universally effective. Emergency medicine pharmacists must identify clinical scenarios where atropine will fail, avoiding dangerous resuscitation delays:
Infranodal AV Conduction Disease : Atropine accelerates conduction through the AV node, but has zero effect on tissue below the AV node (His bundle and bundle branches), which lacks vagal parasympathetic innervation.
Mobitz Type II Second-Degree AV Block : Block is located in the His-Purkinje system. Atropine will increase the sinus rate without improving infranodal conduction, frequently increasing the ratio of non-conducted P waves and worsening bradycardia.
Third-Degree (Complete) AV Block with Wide QRS : The ventricular escape pacemaker originates in infranodal ventricular tissue lacking vagal innervation. Atropine will not accelerate the ventricular rate.
Orthotopic Heart Transplantation : The donor heart is completely surgically denervated during transplantation, severing all autonomic vagal connections. Atropine produces zero chronotropic response.
Acute Myocardial Infarction : In acute coronary ischemia, excessive atropine-induced tachycardia markedly accelerates myocardial oxygen demand ( M V O 2 MVO_2 M V O 2 ), potentially extending myocardial infarction size or precipitating ventricular tachydysrhythmias.
Important
If an unstable bradycardic patient presents with a wide-complex escape rhythm , Mobitz Type II block , third-degree block with wide QRS , or a transplanted heart , do not delay care waiting for atropine response! Immediately initiate transcutaneous pacing or prepare a second-line chronotropic vasoactive infusion.
Second-Line Chronotropic Vasoactive Infusions
When atropine fails, is contraindicated, or while preparing for transcutaneous or transvenous pacing, continuous chronotropic infusions provide reliable hemodynamic and rate support:
Loading diagram...
1. Epinephrine Infusion
Mechanism : Direct, potent alpha-1, beta-1, and beta-2 adrenergic agonist. Beta-1 activation stimulates SA nodal automaticity and AV nodal conduction velocity, while alpha-1 vasoconstriction elevates blood pressure and coronary perfusion.
ACLS Dosing : 2 to 10 mcg/min continuous IV infusion (non-weight-based in adult ACLS), titrated to target heart rate ( > 50 to 60 bpm >50\text{ to }60\text{ bpm} > 50 to 60 bpm ) and resolution of hypoperfusion.
Push-Dose Epinephrine as a Bridge : While waiting for an infusion pump, prepare push-dose epinephrine ( 10 mcg/mL 10\text{ mcg/mL} 10 mcg/mL concentration: dilute 1 mL of 0.1 mg/mL cardiac arrest epinephrine into 9 mL of 0.9% NaCl). Administer 10 to 20 mcg (1 to 2 mL) IV every 2 to 5 minutes as a rapid temporizing bridge.
2. Dopamine Infusion
Mechanism : Endogenous catecholamine precursor. At chronotropic infusion rates ( 5 to 20 mcg/kg/min 5\text{ to }20\text{ mcg/kg/min} 5 to 20 mcg/kg/min ), it primarily stimulates beta-1 adrenergic receptors, enhancing chronotropy and inotropy. At higher doses ( > 10 to 20 mcg/kg/min >10\text{ to }20\text{ mcg/kg/min} > 10 to 20 mcg/kg/min ), alpha-1 mediated vasoconstriction becomes prominent.
ACLS Dosing : 5 to 20 mcg/kg/min continuous IV infusion, starting at 5 mcg/kg/min and titrating by 2.5 to 5 mcg/kg/min every 5 to 10 minutes.
Safety Note : Dopamine is a potent vesicant. Central line infusion is strongly preferred. If peripheral extravasation occurs, immediately infiltrate phentolamine (5 to 10 mg diluted in 10 mL saline) locally to prevent ischemic tissue necrosis.
3. Isoproterenol Infusion
Mechanism : Pure non-selective beta-1 and beta-2 adrenergic agonist with zero alpha-1 activity.
Dosing : 2 to 10 mcg/min continuous IV infusion, titrated to heart rate response.
Clinical Utility : Ideal in orthotopic heart transplant recipients (denervated myocardium retains intact beta receptors) and in bradycardia-dependent polymorphic VT / Torsades de Pointes where accelerating heart rate shortens the QT interval. It causes peripheral vasodilation (beta-2 effect) and must be used with caution in hypotensive shock.
Chronotropic Infusion Comparison Matrix
Vasoactive Agent Standard ACLS Dosing Primary Receptor Profile Clinical Niche & Strengths Cautions & Adverse Effects
Epinephrine 2 to 10 mcg/min IV infusion α 1 , α 2 , β 1 , β 2 \alpha_1, \alpha_2, \beta_1, \beta_2 α 1 , α 2 , β 1 , β 2 Highly potent; reliable chronotropy and vasopressor support in profound shock. Marked tachyarrhythmias, excessive afterload, subendocardial ischemia.
Dopamine 5 to 20 mcg/kg/min IV infusion β 1 > α 1 \beta_1 > \alpha_1 β 1 > α 1 (at > 10 mcg >10\text{ mcg} > 10 mcg ) Weight-based titratable chronotropic and inotropic support. Severe tissue necrosis on extravasation; tachyarrhythmias, excessive M V O 2 MVO_2 M V O 2 .
Isoproterenol 2 to 10 mcg/min IV infusion β 1 , β 2 \beta_1, \beta_2 β 1 , β 2 (Zero α \alpha α ) Denervated heart transplant bradycardia; Torsades de Pointes. Vasodilation/hypotension ( β 2 \beta_2 β 2 ); profound increase in myocardial oxygen demand.
Transcutaneous Pacing (TCP) & Analgesia
Transcutaneous pacing should be initiated immediately in patients with unstable high-grade AV block or when atropine fails. The steps for proper electrical and mechanical capture include:
Pad Placement : Anterior-posterior pad positioning provides lower pacing thresholds than anterolateral placement.
Rate & Current Titration : Set rate to 60 to 80 ppm. Begin at 0 mA and increase current until electrical capture is demonstrated (a distinct pacer spike immediately followed by a wide QRS complex and broad T wave).
Verification of Mechanical Capture : Palpate the femoral or right radial pulse , or observe a pulsatile arterial line waveform corresponding to each pacer spike. Never palpate the carotid pulse (muscular twitching of the neck mimics a pulse).
Analgesia & Sedation : Transcutaneous electrical capture causes painful skeletal muscle contractions. Administer IV fentanyl (25 to 50 mcg) and/or IV midazolam (1 to 2 mg) in conscious patients.
- Special Etiologies and Antidotal Resuscitation
- 1. Beta-Blocker and Calcium Channel Blocker Toxicity
Overdoses of beta-blockers or non-dihydropyridine calcium channel blockers trigger refractory bradycardia, cardiogenic shock, and AV nodal arrest unresponsive to atropine.
High-Dose Insulin Euglycemia Therapy (HIET) : Increases myocardial glucose uptake, restores carbohydrate oxidation in shocked myocytes, and provides potent positive inotropic and chronotropic effects.
Bolus : Regular insulin 1 unit/kg IV bolus .
Continuous Infusion : Regular insulin 0.5 to 1 unit/kg/hour , titrating up to 2 to 10 units/kg/hour in refractory shock.
Dextrose Support : Co-infuse 10% or 50% dextrose (titrated to maintain euglycemia between 100 and 180 mg/dL), monitoring blood glucose every 15 to 30 minutes initially.
Potassium Monitoring : Insulin drives potassium intracellularly; supplement potassium to keep serum levels 3.0 to 3.5 mEq/L 3.0\text{ to }3.5\text{ mEq/L} 3.0 to 3.5 mEq/L .
Calcium Chloride 10% : 1 to 2 g IV over 5 to 10 minutes, repeated every 15 to 20 minutes (up to 3 to 4 doses) or given as a continuous infusion (0.2 to 0.4 mL/kg/h) to overcome competitive L-type channel blockade.
Glucagon : 3.5 to 5 mg (50 to 150 mcg/kg) IV bolus over 3 to 5 minutes, followed by an infusion matching the effective bolus dose per hour. Glucagon bypasses adrenergic receptors to stimulate adenylate cyclase, increasing intracellular cAMP.
2. Hyperkalemia-Induced Conduction Blocks
Severe hyperkalemia ( K + > 6.5 to 7.0 mEq/L K^+ > 6.5\text{ to }7.0\text{ mEq/L} K + > 6.5 to 7.0 mEq/L ) decreases resting membrane potential, leading to sinus arrest, nodal escape rhythms, and sinusoidal QRS widening.
Immediate Intervention : Calcium chloride 1 g IV push over 2 to 5 minutes to restore the threshold potential and stabilize cardiac membranes.
3. Inferior Wall Myocardial Infarction
The right coronary artery (RCA) supplies the sinoatrial node in 60% of patients and the atrioventricular node in 90% (via the AV nodal artery). Inferior STEMI commonly produces severe vagally mediated sinus bradycardia or first/second-degree AV block via the Bezold-Jarisch reflex . This reflex usually responds well to atropine. However, if right ventricular infarction is present (elevated JVD with clear lungs), the patient is preload-dependent; avoid nitrates and volume-depleting agents.